[1] Article Title: Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis
	•	Line(s): L1
	•	Section: Title Page / Header
	•	Quote(s): “Congenital myasthenic syndromes in adults: clinical features, diagnosis and long-term prognosis”

⸻

[2] Publication Year: 2024
	•	Line(s): L51
	•	Section: Title Page Footer
	•	Quote(s): “© The Author(s) 2024. Published by Oxford University Press…”

⸻

[3] Region: Europe
	•	Line(s): L50–L51
	•	Section: Affiliations
	•	Quote(s): “Centre de référence des Maladies Neuromusculaires… Paris, France”

⸻

[4] Country: France
	•	Line(s): L50–L51
	•	Section: Affiliations
	•	Quote(s): “23 specialized neuromuscular centres… in France”

⸻

[5] Coverage Area: National
	•	Line(s): L51
	•	Section: Abstract
	•	Quote(s): “a French nationwide cohort of 235 adult patients…”

⸻

[6] Study Design: Retrospective, observational, multicentre study
	•	Line(s): L179
	•	Section: Materials and Methods
	•	Quote(s): “This retrospective, observational, multicentre study included…”

⸻

[7] Study Population: Adult patients with genetically confirmed CMS
	•	Line(s): L179
	•	Section: Materials and Methods
	•	Quote(s): “all adult patients followed for genetically confirmed CMS…”

⸻

[8] Population Characteristics: Sex, ethnicity, family history, inheritance, age of onset
	•	Line(s): L230–L231
	•	Section: Results – Demographic
	•	Quote(s): “123 were female (52.3%)… 177 patients were Caucasian… Consanguinity was found in 55 cases…”

⸻

[9] Data Source Type: Hospital records
	•	Line(s): L180
	•	Section: Materials and Methods
	•	Quote(s): “clinical data… collected anonymously from the study units’ medical files”

⸻

[10] Data Source Details: 23 University Hospitals in France, part of the French neuromuscular network FILNEMUS
	•	Line(s): L179
	•	Section: Materials and Methods
	•	Quote(s): “…neuromuscular centres of 23 University Hospitals in France… within the French neuromuscular network FILNEMUS.”

⸻

[11] Study Timeline Type: Retrospective
	•	Line(s): L179
	•	Section: Materials and Methods
	•	Quote(s): “This retrospective… study included all adult patients…”

⸻

[12] Number of Sites: Multiple
	•	Line(s): L179
	•	Section: Materials and Methods
	•	Quote(s): “…specialized neuromuscular centres of 23 University Hospitals…”

⸻

[13] Study Start Year: NR
	•	Line(s): NR
	•	Section: NR
	•	Quote(s): NR

⸻

[14] Study End Year: July 31, 2023
	•	Line(s): L179
	•	Section: Materials and Methods
	•	Quote(s): “…CMS until July 2023…”

⸻

[15] Main Ethnicity: Caucasian
	•	Line(s): L230
	•	Section: Results
	•	Quote(s): “177 patients were Caucasian (75.3%)”

⸻

[16] Ethnicity Details: Caucasian 75.3%, North Africa 13.6%, Middle East 4.2%, Sub-Saharan Africa 3.0%, Romani 2.1%, Others 1.7%
	•	Line(s): L230
	•	Section: Results
	•	Quote(s): “177 patients were Caucasian (75.3%), 32 from North Africa (13.6%)…”

⸻

[17] Disease Studied: Congenital myasthenic syndromes (CMS)
	•	Line(s): L51
	•	Section: Abstract
	•	Quote(s): “235 adult patients with genetically confirmed CMS…”

⸻

[18] Diagnosis Method: Genetic testing, clinical features, electrophysiology
	•	Line(s): L204–L209
	•	Section: Methods – Genetic analyses
	•	Quote(s): “PCR, Sanger sequencing, NGS… ENMG, decrement on RNS…”

⸻

[19] Diagnosis Criteria Details: Genetic confirmation and neuromuscular transmission defect via RNS decrement
	•	Line(s): L209
	•	Section: Methods – Clinical and electrophysiological data
	•	Quote(s): “ENMG… decrement superior to 10% on RNS…”

⸻

[20] Disease Phase: Chronic
	•	Line(s): L51
	•	Section: Abstract
	•	Quote(s): “followed in 23 specialized neuromuscular centres”

⸻

[21] Cohort Age Group: Adult
	•	Line(s): L51
	•	Section: Abstract
	•	Quote(s): “adult patients with genetically confirmed CMS”

⸻

[22] Female % in Cohort: 52.3%
	•	Line(s): L230
	•	Section: Results
	•	Quote(s): “123 were female (52.3%)”

⸻

[23] Consanguinity: 55 cases
	•	Line(s): L230
	•	Section: Results
	•	Quote(s): “Consanguinity was found in 55 cases (23.4%)”